Avilar Therapeutics is pioneering the discovery and development of extracellular protein degraders, focusing on a new class of therapeutics called ATACs (ASGPR Targeting Chimeras) that target disease-causing proteins for degradation
Avilar Therapeutics is pioneering the discovery and development of extracellular protein degraders, focusing on a new class of therapeutics called ATACs (ASGPR Targeting Chimeras) that target disease-causing proteins for degradation.